<DOC>
	<DOCNO>NCT01023399</DOCNO>
	<brief_summary>The primary objective study demonstrate non-inferiority Polymerase Chain Reaction ( PCR ) -adjusted adequate clinical parasitological response artesunate plus amodiaquine Day 28 two group patient treat begin artesunate plus amodiaquine implementation program 24 month later . The secondary objective Clinical biological tolerability Evolution gametocyte carriage Proportion patient without fever Day 3 Proportion patient without parasite Day 3 Treatment compliance Impact implementation anemia Measure parasite sensibility amodiaquine</brief_summary>
	<brief_title>Artesunate Plus Amodiaquine Malaria Cote d'Ivoire</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<criteria>Body weight &gt; =5kg Plasmodium falciparum infection parasite density &gt; 2000/ÂµL Fever history fever Able treat oral route No sign severe malaria No know allergy study drug No severe illness underlie diseases No known pregnancy negative urinary pregnancy test woman child bear age No participation another ongoing clinical study The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>